Bms-986278 clinical trial

Author: lzru

August undefined, 2024

WebMar 1, 2024 · Abstract. In a Phase 2 clinical trial, BMS-986020, a lysophosphatidic acid receptor-1 (LPA 6.2 μM) and inhibited BA canalicular efflux in human hepatocytes (68% … WebJan 26, 2024 · BMS-986020, BMS-986234 and BMS-986278, are three lysophosphatidic acid receptor 1 (LPA1) antagonists that were or are being investigated for treatment of idiopathic pulmonary fibrosis (IPF).

BMS-986278 CAS#2170126-74-4 LPA1 antagonist MedKoo

WebA Study Measuring the Effectiveness, Safety, and Tolerability of BMS-986278 in Participants With Lung Fibrosis Latest version (submitted March 17, 2024) on ClinicalTrials.gov A … WebBristol Myers Squibb is committed to sustaining its strong leadership and legacy in the development of transformational therapeutics for treating patients with malignant and benign hematological conditions. • Our focus is on Multiple Myeloma, Lymphoma and CLL, MDS, AML, MPNs (e.g., myelofibrosis) and thalassemias katharine hepburn movie in italy

NCT04308681 Study Connect

WebJul 13, 2024 · The Autotaxin (ATX)-Lysophosphatidic Acid (LPA) Axis. Phospholipid growth factors (PLGFs) are a family of lipids with growth factor-like properties. Lysophosphatidic acid (LPA) is a member of the PLGF family that promotes a diverse range of physiological cellular functions by binding to specific G-protein-coupled receptors (LPAR 1–6), present ... WebClinical Trials For: BMS-986158 ± Fedratinib, BET Inhibitor ± JAK2 Inhibitor in DIPSS–Intermediate or High-risk Myelofibrosis A Study to Assess the Safety and … WebMar 1, 2024 · In a Phase 2 clinical trial, BMS-986020, a lysophosphatidic acid receptor-1 (LPA 1 ) antagonist, produced hepatobiliary toxicity (increased ALT, AST, and ALP; cholecystitis) and increases in plasma bile acids (BA). ... (BMS-986234 and BMS-986278). BMS-986020 inhibited hepatic BA efflux transporters BSEP (IC 50 1.8 μM), MRP3 (IC 50 … katharine hepburn long day\\u0027s journey

Clinical Trial on BMS-986278 - Clinical Trials Registry - ICH GCP

Study to Assess the Way the Body Absorbs, Distributes, Breaks …

WebDec 1, 2024 · Clinical trials showed that treatment with BMS-986020 in patients with idiopathic pulmonary fibrosis could ameliorate the decline in pulmonary function and improve the biomarkers of fibrosis or inflammation compared ... BMS-986278 is a potent antagonist that blocks LPA 1-mediated G i, G q, G 12, and β-arrestin signaling pathways in primary ... WebIntroduction: The LPA1 receptor is implicated in IPF pathogenesis. BMS-986278 is a potent small molecule LPA1 receptor antagonist being investigated for IPF. This study evaluated the safety, tolerability, and PK of oral BMS-986278 in healthy participants (ppts). Methods: IM027-009 is a phase 1, double-blind, placebo (PBO)-controlled, randomized study in … katharine hepburn john wayne movieWebBMS-986278 is a potent and orally active lysophosphatidic acid receptor 1 (LPA1) antagonist, with Kbs of 6.9 nM and 4.0 nM for human and mouse LPA1, respectively. BMS-986278 can be used for the research of pulmonary fibrotic diseases. ... Clinical Trial: Molecular Weight: 445.51 Appearance: Solid Formula: C 22 H 31 N 5 O 5. CAS No. … lax to tampa flights

"WebBMS-986278 is a potent lysophosphatidic acid receptor 1 (LPA1) antagonist, with a human LPA1 Kb of 6.9 nM. On the basis of its in vivo efficacy in rodent chronic lung fibrosis models and excellent overall ADME (absorption, distribution, metabolism, excretion) properties in multiple preclinical species, BMS-986278 was advanced into clinical trials, including an … " - Bms-986278 clinical trial

Bms-986278 clinical trial

WebBMS-986278 for Pulmonary Fibrosis Clinical Trial 2024 Power Apply to this Phase 2 clinical trial treating Pulmonary Fibrosis, Fibrosis. Get access to cutting edge treatment via BMS …

Did you know?

WebJan 12, 2024 · Completed. Idiopathic Pulmonary Fibrosis (IPF) BMS-986278. Pirfenidone. Salt Lake City, Utah. PRA Health Sciences - Salt Lake. WebNov 11, 2024 · The oxycyclohexyl acid BMS-986278 (33) is a potent lysophosphatidic acid receptor 1 (LPA 1) antagonist, with a human LPA 1 K b of 6.9 nM.The structure-activity relationship (SAR) studies starting from the LPA 1 antagonist clinical compound BMS-986020 (1), which culminated in the discovery of 33, are discussed.The detailed in vitro …

WebA Study Measuring the Effectiveness, Safety, and Tolerability of BMS-986278 in Participants With Lung Fibrosis - IM027-040. Updated: 3 December, 2024 ClinicalTrials.gov. About … WebJan 13, 2024 · A Phase 1, 2-Part, Randomized, Double-Blind, Placebo-controlled, Multiple Dose Study to Test the Potential Interaction of a PDE5 Inhibitor With BMS-986278 and to …

WebFeb 3, 2024 · Clinical trial for Study to Investigate the Safety, Tolerability, and Pharmacokinetic Profile With Oral AB521 in Healthy Volunteers. Updated 02/03/2024. Toggle navigation. ... NCT03712540 - An Investigational Study of Experimental Medication BMS-986278 Given With the Antibiotic Rifampin in Healthy Participants Phase 1: … WebSep 28, 2024 · Maximum observed plasma concentration (Cmax) of BMS-986278 [ Time Frame: Up to 15 days ] ... For more information regarding Bristol-Myers Squibb Clinical Trial participation, please visit www.BMSStudyConnect.com. ... Bristol-Myers Squibb: ClinicalTrials.gov Identifier: NCT04567667 Other Study ID Numbers:

WebSep 28, 2024 · Specific to PF-ILD, the LPA 1 antagonist, BMS-986278, has shown promise in preclinical and phase I studies (67, 68) and is currently in phase 2 clinical trials, with study arms for both IPF and PF ...

WebThe purpose of this study is to provide an initial evaluation of the effectiveness of BMS-986278 in participants with lung fibrosis, to demonstrate the safety of BMS-986278, and … lax to tehachapiWebMar 28, 2024 · March 28, 2024 updated by: Bristol-Myers Squibb A Double-blind, Placebo-controlled, Randomized, Single and Multiple Dose Study to Evaluate the … katharine hepburn movie list by yearWebDec 20, 2024 · A Phase 1, 2-Part, Randomized, Double-Blind, Placebo-controlled, Multiple Dose Study to Test the Potential Interaction of a PDE5 Inhibitor With BMS-986278 and to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of BMS-986278 in Healthy Adult Participants (Part 1) and in Japanese Participants (Part 2) The … lax to tampa direct flightsWebMar 28, 2024 · A Study to Evaluate the Drug Levels, Safety, and Tolerability of BMS-986278 in Healthy Chinese Participants March 28, 2024 updated by: Bristol-Myers Squibb A Double-blind, Placebo-controlled, Randomized, Single and Multiple Dose Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of BMS-986278 in Healthy Chinese … lax to tampa flightWebMar 12, 2024 · December 3, 2024 updated by: Bristol-Myers Squibb A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase 2 Study of the Efficacy and the … lax to tampa fl flightsWebMar 1, 2024 · BMS-986234 and BMS-986278 are both potent LPA 1 antagonists that are structurally distinct from BMS-986020 (Cheng et al., 2024) (Fig. 1).BMS-986234 was discontinued prior to clinical development due to an unfavorable nonclinical pharmacokinetic profile (Cheng et al., 2024).BMS-986278 is currently being evaluated in … katharine hepburn movies ok.ruWebThe oxycyclohexyl acid BMS-986278 (33) is a potent lysophosphatidic acid receptor 1 (LPA1) antagonist, with a human LPA1 Kb of 6.9 nM. The structure–activity relationship (SAR) studies starting from the LPA1 antagonist clinical compound BMS-986020 (1), which culminated in the discovery of 33, are discussed. The detailed in vitro and in vivo … katharine hepburn movie quotes